

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 1 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 1. Identification

**GHS product identifier** : Docetaxel Injection, USP  
**Other means of identification** : Not available.  
**Product type** : Liquid.

**Relevant identified uses of the substance or mixture and uses advised against**

**Product use** : Pharmaceuticals. (For intended use only.)  
 Observe technical data sheet/instructions for use.  
 Specific Treatments: Anticancer

**Area of application** : Professional applications.

**Supplier's details** : Meitheal Pharmaceuticals, Inc.  
 8700 W. Bryn Mawr, Suite 600S  
 Chicago, IL 60631  
  
 Telephone: 224-443-4617  
 www.meithealpharma.com

**e-mail address of person responsible for this SDS** : info@meithealpharma.com

**Emergency telephone number (with hours of operation)** : 844-824-8426 (Monday - Friday, 08:00 - 18:00 CST)

## Section 2. Hazards identification

**OSHA/HCS status** : This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200).

**Classification of the substance or mixture** : H320 EYE IRRITATION - Category 2B  
 H360 TOXIC TO REPRODUCTION - Category 1B  
 H362 TOXIC TO REPRODUCTION - Effects on or via lactation

**GHS label elements**

**Hazard pictograms** :



**Signal word** : Danger

**Hazard statements** : H320 - Causes eye irritation.  
 H360 - May damage fertility or the unborn child.  
 H362 - May cause harm to breast-fed children.

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 2 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 2. Hazards identification

### Precautionary statements

#### Prevention

- : P201 - Obtain special instructions before use.
- P202 - Do not handle until all safety precautions have been read and understood.
- P280 - Wear protective gloves, protective clothing and eye or face protection.
- P263 - Avoid contact during pregnancy or while nursing.
- P270 - Do not eat, drink or smoke when using this product.
- P264 - Wash thoroughly after handling.

#### Response

- : P308 + P313 - IF exposed or concerned: Get medical advice or attention.
- P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
- P337 + P313 - If eye irritation persists: Get medical advice or attention.

#### Storage

- : P405 - Store locked up.

#### Disposal

- : P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.

#### Hazards not otherwise classified

- : None known.

## Section 3. Composition/information on ingredients

- Substance/mixture** : Mixture
- Other means of identification** : Not available.

Ingredient name	Other names	%	CAS number
Poly(oxy-1,2-ethanediyl), $\alpha$ -hydro- $\omega$ -hydroxy-Ethane-1,2-diol, ethoxylated	-	$\geq 50 - \leq 75$	25322-68-3
Sorbitan monooleate, ethoxylated	-	$\geq 10 - \leq 25$	9005-65-6
Benzenepropanoic acid, $\beta$ -[[[(1,1-dimethylethoxy) carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)-	-	$< 1$	114977-28-5
citric acid	-	$< 1$	77-92-9
nitrogen	-	$\leq 0.1$	7727-37-9
Ethanol	-	$\leq 0.1$	64-17-5

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

**There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health and hence require reporting in this section.**

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 3 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 4. First aid measures

### Description of necessary first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. If irritation persists, get medical attention.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.
- Ingestion** : Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

### Most important symptoms/effects, acute and delayed

#### Potential acute health effects

- Eye contact** : Causes eye irritation.
- Inhalation** : No known significant effects or critical hazards.
- Skin contact** : No known significant effects or critical hazards.
- Ingestion** : No known significant effects or critical hazards.

#### Over-exposure signs/symptoms

- Eye contact** : Adverse symptoms may include the following:  
irritation  
watering  
redness
- Inhalation** : Adverse symptoms may include the following:  
reduced fetal weight  
increase in fetal deaths  
skeletal malformations
- Skin contact** : Adverse symptoms may include the following:  
reduced fetal weight  
increase in fetal deaths  
skeletal malformations

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 4 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 4. First aid measures

**Ingestion** : Adverse symptoms may include the following:  
 reduced fetal weight  
 increase in fetal deaths  
 skeletal malformations

### Indication of immediate medical attention and special treatment needed, if necessary

**Notes to physician** : Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.

**Specific treatments** : No specific treatment.

**Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

See toxicological information (Section 11)

## Section 5. Fire-fighting measures

### Extinguishing media

**Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.

**Unsuitable extinguishing media** : Do not use water jet.

**Specific hazards arising from the chemical** : In a fire or if heated, a pressure increase will occur and the container may burst.

**Hazardous thermal decomposition products** : Decomposition products may include the following materials:  
 carbon dioxide  
 carbon monoxide

**Special protective actions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

**Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 5 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 6. Accidental release measures

### Personal precautions, protective equipment and emergency procedures

**For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

**For emergency responders** : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

**Environmental precautions** : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

### Methods and materials for containment and cleaning up

**Small spill** : Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

**Large spill** : Stop leak if without risk. Move containers from spill area. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.

## Section 7. Handling and storage

### Precautions for safe handling

**Protective measures** : Put on appropriate personal protective equipment (see Section 8). Avoid exposure - obtain special instructions before use. Avoid contact during pregnancy or while nursing. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapor or mist. If during normal use the material presents a respiratory hazard, use only with adequate ventilation or wear appropriate respirator. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

**Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 6 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 7. Handling and storage

**Conditions for safe storage, including any incompatibilities** : Store between the following temperatures: 20 to 25°C (68 to 77°F). Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

## Section 8. Exposure controls/personal protection

### Control parameters

#### Occupational exposure limits

<b>Ingredient name</b>	<b>Exposure limits</b>
Poly(oxy-1,2-ethanediyl), $\alpha$ -hydro- $\omega$ -hydroxy- Ethane-1,2-diol, ethoxylated	<b>AIHA WEEL (United States, 7/2018).</b> TWA: 10 mg/m <sup>3</sup> 8 hours.
Sorbitan monooleate, ethoxylated	None.
Benzenepropanoic acid, $\beta$ -[[[(1,1-dimethylethoxy) carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R, 9S,11S,12S,12aR,12bS)-12b- (acetyloxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b- dodecahydro-4,6,11-trihydroxy-4a,8,13, 13-tetramethyl- 5-oxo-7,11-methano- 1H-cyclodeca[3, 4]benz[1,2-b] oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)-	None.
citric acid	None.
nitrogen	<b>ACGIH TLV (United States, 3/2020). Oxygen Depletion [Asphyxiant].</b>
Ethanol	<b>ACGIH TLV (United States, 3/2020).</b> STEL: 1000 ppm 15 minutes. <b>NIOSH REL (United States, 10/2016).</b> TWA: 1000 ppm 10 hours. TWA: 1900 mg/m <sup>3</sup> 10 hours. <b>OSHA PEL (United States, 5/2018).</b> TWA: 1000 ppm 8 hours. TWA: 1900 mg/m <sup>3</sup> 8 hours.

**Appropriate engineering controls** : If user operations generate dust, fumes, gas, vapor or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits.

**Environmental exposure controls** : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

### Individual protection measures

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 7 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 8. Exposure controls/personal protection

- Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
- Eye/face protection** : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.
- Skin protection**
  - Hand protection** : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.
  - Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
  - Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

## Section 9. Physical and chemical properties

### Appearance

- Physical state** : Liquid. [Clear.]
- Color** : Colorless to light yellow.
- Odor** : Alcohol-like.
- Odor threshold** : Not available.
- pH** : 3.5 to 5.5
- Melting point** : Not available.
- Boiling point** : Not available.
- Flash point** : Not available.
- Evaporation rate** : Not available.
- Flammability (solid, gas)** : Not applicable.
- Lower and upper explosive (flammable) limits** : Not available.
- Vapor pressure** : Not available.

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 8 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 9. Physical and chemical properties

<b>Vapor density</b>	: Not available.
<b>Relative density</b>	: Not available.
<b>Density</b>	: Not available.
<b>Solubility</b>	: Not available.
<b>Solubility in water</b>	: Not available.
<b>Partition coefficient: n-octanol/water</b>	: Not available.
<b>Auto-ignition temperature</b>	: Not available.
<b>Decomposition temperature</b>	: Not available.
<b>SADT</b>	: Not available.
<b>Viscosity</b>	: Not available.
<b>Flow time (ISO 2431)</b>	: Not available.

## Section 10. Stability and reactivity

<b>Reactivity</b>	: No specific test data related to reactivity available for this product or its ingredients.
<b>Chemical stability</b>	: The product is stable.
<b>Possibility of hazardous reactions</b>	: Under normal conditions of storage and use, hazardous reactions will not occur. Under normal conditions of storage and use, hazardous polymerization will not occur.
<b>Conditions to avoid</b>	: Protect from light. Keep away from heat, sparks and flame. Do not freeze.
<b>Incompatible materials</b>	: No specific data.
<b>Hazardous decomposition products</b>	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## Section 11. Toxicological information

### Information on toxicological effects

#### Acute toxicity



<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 9 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 11. Toxicological information

Product/ingredient name	Result	Species	Dose	Exposure
Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-Ethane-1,2-diol, ethoxylated	LD50 Dermal	Rat - Male, Female	>2000 mg/kg	-
	LD50 Oral	Rat - Female	>2000 mg/kg	-
Sorbitan monooleate, ethoxylated	LD50 Oral	Rat	34500 uL/kg	-
	LD50 Dermal	Rat - Male, Female	>2000 mg/kg	-
Citric acid	LD50 Oral	Rat	3 g/kg	-
	LC50 Inhalation Vapor	Rat	124700 mg/m <sup>3</sup>	4 hours
	LD50 Oral	Rat	7 g/kg	-

### Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-Ethane-1,2-diol, ethoxylated	Eyes - Mild irritant	Rabbit	-	24 hours 500 mg	-
	Eyes - Mild irritant	Rabbit	-	500 mg	-
	Skin - Mild irritant	Rabbit	-	24 hours 500 mg	-
Sorbitan monooleate, ethoxylated	Skin - Mild irritant	Rabbit	-	500 mg	-
	Eyes - Mild irritant	Rabbit	-	150 mg	-
	Eyes - Severe irritant	Rabbit	-	24 hours 750 ug	-
Citric acid	Skin - Mild irritant	Rabbit	-	24 hours 500 mg	-
	Skin - Moderate irritant	Rabbit	-	0.5 MI	-
	Eyes - Severe irritant	Rabbit	-	500 milligrams	-

### Sensitization

Not available.

### Mutagenicity

**Conclusion/Summary** : Not available.

### Carcinogenicity

**Conclusion/Summary** : Not available.

### Classification

Product/ingredient name	OSHA	IARC	NTP
Ethanol	-	1	-

### Reproductive toxicity

**Conclusion/Summary** : Not available.

### Teratogenicity

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 10 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 11. Toxicological information

**Conclusion/Summary** : Not available.

### Specific target organ toxicity (single exposure)

Name	Category	Route of exposure	Target organs
citric acid	Category 3	-	Respiratory tract irritation
Ethanol	Category 3	-	Narcotic effects

### Specific target organ toxicity (repeated exposure)

Name	Category	Route of exposure	Target organs
Benzenepropanoic acid, $\beta$ -[[[(1,1-dimethylethoxy) carbonyl]amino]- $\alpha$ - hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b- (acetyloxy)-12 -(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b- dodecahydro-4,6,11-trihydroxy-4a,8,13, 13-tetramethyl- 5-oxo-7,11-methano- 1H-cyclodeca[3, 4]benz[1,2-b] oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)-	Category 1	-	-

### Aspiration hazard

Not available.

**Information on the likely routes of exposure** : Routes of entry anticipated: Oral, Dermal, Inhalation.

### Potential acute health effects

- Eye contact** : Causes eye irritation.
- Inhalation** : No known significant effects or critical hazards.
- Skin contact** : No known significant effects or critical hazards.
- Ingestion** : No known significant effects or critical hazards.

### Symptoms related to the physical, chemical and toxicological characteristics

**Eye contact** : Adverse symptoms may include the following:  
irritation  
watering  
redness

**Inhalation** : Adverse symptoms may include the following:  
reduced fetal weight  
increase in fetal deaths  
skeletal malformations

**Skin contact** : Adverse symptoms may include the following:  
reduced fetal weight  
increase in fetal deaths  
skeletal malformations

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 11 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

**Section 11. Toxicological information**

**Ingestion** : Adverse symptoms may include the following:  
 reduced fetal weight  
 increase in fetal deaths  
 skeletal malformations

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

**Potential immediate effects** : Not available.

**Potential delayed effects** : Not available.

Long term exposure

**Potential immediate effects** : Not available.

**Potential delayed effects** : Not available.

Potential chronic health effects

Not available.

**General** : No known significant effects or critical hazards.

**Carcinogenicity** : No known significant effects or critical hazards.

**Mutagenicity** : No known significant effects or critical hazards.

**Teratogenicity** : May damage the unborn child.

**Developmental effects** : May cause harm to breast-fed children.

**Fertility effects** : May damage fertility.

Numerical measures of toxicity

Acute toxicity estimates

Product/ingredient name	Oral (mg/kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapors) (mg/l)	Inhalation (dusts and mists) (mg/l)
Docetaxel Injection, USP	2547.3	2547.3	N/A	N/A	N/A
Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-	2500	2500	N/A	N/A	N/A
Ethane-1,2-diol, ethoxylated	3000	2500	N/A	N/A	N/A
citric acid	7000	N/A	N/A	N/A	N/A
Ethanol				124.7	N/A

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 12 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 12. Ecological information

### Toxicity

Product/ingredient name	Result	Species	Exposure
Poly(oxy-1,2-ethanediyl), $\alpha$ -hydro- $\omega$ -hydroxy-Ethane-1,2-diol, ethoxylated citric acid	Acute LC50 >1000000 $\mu$ g/l Fresh water	Fish - Salmo salar - Parr	96 hours
	Acute LC50 160000 $\mu$ g/l Marine water	Crustaceans - Carcinus maenas - Adult	48 hours
Ethanol	Acute EC50 17.921 mg/l Marine water	Algae - Ulva pertusa	96 hours
	Acute EC50 2000 $\mu$ g/l Fresh water	Daphnia - Daphnia magna	48 hours
	Acute LC50 25500 $\mu$ g/l Marine water	Crustaceans - Artemia franciscana - Larvae	48 hours
	Acute LC50 42000 $\mu$ g/l Fresh water	Fish - Oncorhynchus mykiss	4 days
	Chronic NOEC 4.995 mg/l Marine water	Algae - Ulva pertusa	96 hours
	Chronic NOEC 100 ul/L Fresh water	Daphnia - Daphnia magna - Neonate	21 days
	Chronic NOEC 0.375 ul/L Fresh water	Fish - Gambusia holbrooki - Larvae	12 weeks

**Conclusion/Summary** : Not available.

### Persistence and degradability

Product/ingredient name	Test	Result	Dose	Inoculum
Poly(oxy-1,2-ethanediyl), $\alpha$ -hydro- $\omega$ -hydroxy-Ethane-1,2-diol, ethoxylated	OECD 301D Ready Biodegradability - Closed Bottle Test	74.85 % - Readily - 28 days	4 mg/l	-
Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability	
Poly(oxy-1,2-ethanediyl), $\alpha$ -hydro- $\omega$ -hydroxy-Ethane-1,2-diol, ethoxylated citric acid	-	-	Readily	
Ethanol	-	-	Readily	

### Bioaccumulative potential

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 13 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 12. Ecological information

Product/ingredient name	LogP <sub>ow</sub>	BCF	Potential
Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-Ethane-1,2-diol, ethoxylated	-	3.2	low
Benzenepropanoic acid, β-[[[(1,1-dimethylethoxy) carbonyl]amino]-α- hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12 -(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano- 1H-cyclodeca[3, 4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-	2.83	-	low
citric acid	-1.8	-	low
nitrogen	0.67	-	low
Ethanol	-0.35	-	low

### Mobility in soil

**Soil/water partition coefficient (K<sub>oc</sub>)**

: Not available.

### Other adverse effects

: No known significant effects or critical hazards.

## Section 13. Disposal considerations

### Disposal methods

: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.



<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 14 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 14. Transport information

	DOT Classification	IMDG	IATA
<b>UN number</b>	Not regulated.	Not regulated.	Not regulated.
<b>UN proper shipping name</b>	-	-	-
<b>Transport hazard class(es)</b>	-	-	-
<b>Packing group</b>	-	-	-
<b>Environmental hazards</b>	No.	No.	No.

### Additional information

**Special precautions for user** : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

**Transport in bulk according to IMO instruments** : Not available.

## Section 15. Regulatory information

**U.S. Federal regulations** : TSCA 8(a) CDR Exempt/Partial exemption: Not determined  
United States inventory (TSCA 8b): Not determined.

**Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs)** : Not listed

**Clean Air Act Section 602 Class I Substances** : Not listed

**Clean Air Act Section 602 Class II Substances** : Not listed

**DEA List I Chemicals (Precursor Chemicals)** : Not listed

**DEA List II Chemicals (Essential Chemicals)** : Not listed

### SARA 302/304

#### Composition/information on ingredients

No products were found.

<b>SDS Title:</b> Docetaxel Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000045	<b>Page Number:</b> Page 15 of 17
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 25, 2021	<b>Version number:</b> 1.0

## Section 15. Regulatory information

**SARA 304 RQ** : Not applicable.

**SARA 311/312**

**Classification** : EYE IRRITATION - Category 2B  
 TOXIC TO REPRODUCTION - Category 1B  
 TOXIC TO REPRODUCTION - Effects on or via lactation

**Composition/information on ingredients**

Name	%	Classification
Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-Ethane-1,2-diol, ethoxylated	≥50 - ≤75	EYE IRRITATION - Category 2B
Sorbitan monooleate, ethoxylated	≥10 - ≤25	EYE IRRITATION - Category 2B
Benzenepropanoic acid, β-[[[(1,1-dimethylethoxy) carbonyl]amino]-α- hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12 -(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano- 1H-cyclodeca[3, 4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-	<1	EYE IRRITATION - Category 2A GERM CELL MUTAGENICITY - Category 2 TOXIC TO REPRODUCTION - Category 1B TOXIC TO REPRODUCTION - Effects on or via lactation SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) - Category 1
citric acid	<1	COMBUSTIBLE DUSTS SKIN IRRITATION - Category 2 EYE IRRITATION - Category 2A SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3
nitrogen	≤0.1	GASES UNDER PRESSURE - Compressed gas SIMPLE ASPHYXIANTS
Ethanol	≤0.1	FLAMMABLE LIQUIDS - Category 2 EYE IRRITATION - Category 2A SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Narcotic effects) - Category 3 HNOC - Defatting irritant

**SARA 313**

Not applicable.

**State regulations**

- Massachusetts** : None of the components are listed.
- New York** : None of the components are listed.
- New Jersey** : None of the components are listed.
- Pennsylvania** : None of the components are listed.

SDS Title: Docetaxel Injection, USP Safety Data Sheet	SDS Number: SDS-000045	Page Number: Page 16 of 17
Function: Regulatory Affairs	Effective Date: January 25, 2021	Version number: 1.0

## Section 15. Regulatory information

### California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

### International regulations

#### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

#### Montreal Protocol

Not listed.

#### Stockholm Convention on Persistent Organic Pollutants

Not listed.

#### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

#### UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

## Section 16. Other information

### Hazardous Material Information System (U.S.A.)

Health	*	4
Flammability		0
Physical hazards		0

Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

### National Fire Protection Association (U.S.A.)



Reprinted with permission from NFPA 704, Identification of the Hazards of Materials for Emergency Response Copyright ©1997, National Fire Protection Association, Quincy, MA 02269. This reprinted material is not the complete and official position of the National Fire Protection Association, on the referenced subject which is represented only by the standard in its entirety.



SDS Title: Docetaxel Injection, USP Safety Data Sheet	SDS Number: SDS-000045	Page Number: Page 17 of 17
Function: Regulatory Affairs	Effective Date: January 25, 2021	Version number: 1.0

## Section 16. Other information

Copyright ©2001, National Fire Protection Association, Quincy, MA 02269. This warning system is intended to be interpreted and applied only by properly trained individuals to identify fire, health and reactivity hazards of chemicals. The user is referred to certain limited number of chemicals with recommended classifications in NFPA 49 and NFPA 325, which would be used as a guideline only. Whether the chemicals are classified by NFPA or not, anyone using the 704 systems to classify chemicals does so at their own risk.

### Procedure used to derive the classification

Classification	Justification
EYE IRRITATION - Category 2B	Calculation method
TOXIC TO REPRODUCTION - Category 1B	Calculation method
TOXIC TO REPRODUCTION - Effects on or via lactation	Calculation method

### History

<b>Date of issue/Date of revision</b>	: 01/25/2021
<b>Date of previous issue</b>	: No previous validation
<b>Version</b>	: 1.0
<b>Prepared by</b>	: Sphera Solutions
<b>Key to abbreviations</b>	: ATE = Acute Toxicity Estimate AMP = Acceptable maximum peak above the acceptable ceiling concentration for an 8-hr shift BCF = Bioconcentration Factor GHS = Globally Harmonized System of Classification and Labelling of Chemicals IATA = International Air Transport Association IBC = Intermediate Bulk Container IMDG = International Maritime Dangerous Goods LogPow = logarithm of the octanol/water partition coefficient MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution) N/A = Not available UN = United Nations
<b>References</b>	: HCS (U.S.A.)- Hazard Communication Standard International transport regulations

☑ Indicates information that has changed from previously issued version.

### Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.